# OnCo record nct07227311 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07227311/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07227311", "NCT07227311" ;
  schema:name "A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult"@en ;
  schema:alternateName "DREAMM-15"@en ;
  schema:description "A phase 2 trial of Belantamab mafodotin, Dexamethasone, Pomalidomide in multiple myeloma, run by GlaxoSmithKline, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07227311/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07227311> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2026-04-15" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/carfilzomib/> ;
  onco:companies <https://onco.cc/companies/gsk/> .